Grupo de Cáncer de Próstata

INVESTIGACIÓN CLÍNICA

El principal objetivo de nuestro grupo es desarrollar nuevos fármacos y estrategias terapéuticas para el cáncer de próstata avanzado. Combinamos ensayos clínicos, estudios moleculares correlativos y estudios mecanísticos siguiendo un enfoque de investigación bidireccional, del laboratorio a la práctica clínica y de vuelta al laboratorio.

Integramos experiencia multidisciplinar en investigación clínica, biología del cáncer, genómica y transcriptómica, bioinformática, biopsia líquida y ciencia de datos clínicos para avanzar en la medicina de precisión para los pacientes con cáncer de próstata. Para apoyar este objetivo, hemos establecido una plataforma de recogida longitudinal de muestras biológicas y datos de pacientes con cáncer de próstata avanzado. Estas muestras nos permiten estudiar la evolución de la enfermedad y generar modelos de laboratorio derivados de pacientes, que utilizamos para investigar nuevas estrategias terapéuticas.

Nuestra cartera de ensayos clínicos abarca todo el continuo de la enfermedad, con especial atención a los ensayos de fases tempranas de nuevos compuestos y a las estrategias terapéuticas basadas en la biología de la enfermedad. Los estudios clínicos promovidos por investigadores constituyen un elemento central de nuestra estrategia de investigación y proporcionan una plataforma para desarrollar estudios correlativos. Actualmente actuamos como laboratorio central de dos ensayos clínicos académicos multicéntricos y gestionamos el repositorio de muestras de IRONMAN, una iniciativa internacional destinada a crear una amplia base de datos clínicos y de muestras biológicas de pacientes con cáncer de próstata metastásico.

Nuestras principales líneas de investigación incluyen: 1) comprender cómo los cánceres de próstata se adaptan a los tratamientos sistémicos, con especial atención al ciclo celular y a la regulación de la respuesta al daño del ADN; 2) desarrollar nuevos enfoques de caracterización molecular mediante muestras de tejido y biopsia líquida para mejorar la estratificación de los pacientes; y 3) identificar biomarcadores pronósticos y predictivos que permitan tomar decisiones terapéuticas más precisas. Para alcanzar estos objetivos, estudiamos modelos in vitro e in vivo, incluidos xenoinjertos derivados de pacientes (PDX) que participan en nuestros estudios clínicos. Analizamos la genómica y la transcriptómica de muestras clínicas, con especial atención al ADN tumoral circulante (ctDNA) y a las vesículas extracelulares derivadas del tumor. Además, utilizamos bases de datos clinicogenómicas propias y de acceso público para avanzar en la atención oncológica de precisión.

También lideramos el estudio HOPE-Prostate, un proyecto colaborativo con el Grupo SOLTI y sociedades médicas españolas especializadas en cáncer de próstata para empoderar a los pacientes y facilitar su acceso a pruebas moleculares. En el marco de esta iniciativa, más de 200 pacientes de toda España se han incorporado al estudio y han aportado datos y muestras biológicas.

Nos sentimos honrados de contar con el apoyo financiero de los Congressionally Directed Medical Research Programs (CDMRP) del Departamento de Defensa de Estados Unidos, el Ministerio de Sanidad de España, la Fundación CRIS contra el Cáncer, la Asociación Española Contra el Cáncer (AECC), la Fundación FERO, la Prostate Cancer Foundation y la Fundación ”la Caixa”. Asimismo, desarrollamos proyectos conjuntos con empresas biotecnológicas y farmacéuticas para impulsar nuevas estrategias terapéuticas.

Para acelerar los avances, apostamos por la ciencia colaborativa. Participamos activamente en colaboraciones que permiten compartir recursos y conocimientos entre múltiples grupos de investigación de todo el mundo.

Joaquin Mateo

Jefe de grupo

Biosketch

Líneas de investigación

Comprender por qué algunos tratamientos para el cáncer de próstata solo funcionan en determinados pacientes y no en otros, con el objetivo de ofrecer a cada paciente la mejor opción terapéutica para su caso concreto.
Evaluar y desarrollar nuevas estrategias terapéuticas para el cáncer de próstata mediante ensayos clínicos.
Estudiar cómo se adapta el cáncer de próstata al tratamiento, con especial atención a las nuevas vulnerabilidades terapéuticas que pueden ayudar a retrasar la recaída de la enfermedad.
Investigar la heterogeneidad tumoral en respuesta al tratamiento mediante modelos preclínicos y xenoinjertos derivados de pacientes (PDX), así como a través del análisis de biopsias de pacientes.
Desarrollar nuevas herramientas de biopsia líquida que permitan monitorizar la evolución tumoral.
Desarrollar ensayos clínicos académicos para validar nuestros resultados de laboratorio en la práctica clínica y utilizar biopsias de pacientes para llevar a cabo estudios correlativos.

Equipo

Jefe de grupo

Joaquin Mateo

Investigadora sénior

Irene Casanova

Staff researcher

Gisela Mir

Oncólogos médicos

Pablo Cresta, Maria Dolores Fenor de la Maza

Investigadores postdoctorales

Nicolas Anselmino, Richard Norris

Clinical Research Fellow

Francesca Zacchi

Investigadores predoctorales

Julian Brandariz, Youhao Chen, Victor Esquefa, Andrei Salca, Roma Sunder

Técnicos de laboratorio

Teresa Casals, Lara de Llobet, Laura Martinez, Mar More, Anna Oliveira

Gestora de datos clínicos

Haitham Alatoom

Coordinador de Investigación Clínica

Maria del Mar Suanes, Erika Saenz

Enfermera de investigación

Ana Maria Castañeira, Helena Palma

Bioinformático

Daniel Aguilar, Manuel Ramos

Publicaciones

Publicaciones científicas más relevantes
1. Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J. Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. NPJ Precis Oncol. 2025 Nov 26;9(1):407.
2. Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976.
3. Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937.
4. Gumpert N, Sagie S, Arnedo-Pac C, Babu T, Weller C, Gonzalez-Perez A, Wang Y, Michel Todó L, Levy R, Chen X, Greenberg P, Dayan-Rubinov M, Yakubovich E, Wasserman-Bartov T, Zerbib M, Gong J, Rebernick RJ, Oliveira Tercero A, Agundez Muriel L, Benedek G, Kedmi M, Oren R, Ben-Dor S, Levin Y, Troyanskaya OG, Munzur AD, Wyatt AW, Cieslik MP, Quigley DA, Van Allen EM, Anandasabapathy N, Mateo J, Yang X, Martínez-Jiménez F, Lopez-Bigas N, Samuels Y. Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. Cancer Discov. 2025. doi: 10.1158/2159-8290.CD-24-1213.
5. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7.
6. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274.
7. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583.
8. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264.
Todas las publicaciones
1. Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J. Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. NPJ Precis Oncol. 2025 Nov 26;9(1):407. doi: 10.1038/s41698-025-01179-y. PMID: 41299058; PMCID: PMC12750001.
2. Grussu F, Grigoriou A, Bernatowicz K, Palombo M, Casanova-Salas I, Navarro-Garcia D, Barba I, Simonetti S, Serna G, Macarro C, Voronova AK, Garay V, Corral JF, Vidorreta M, García-Polo García P, Merino X, Mast R, Rosón N, Escobar M, Vieito M, Toledo R, Nuciforo P, Mateo J, Garralda E, Perez-Lopez R. Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI. Commun Med (Lond). 2025 Nov 20;5(1):535. doi: 10.1038/s43856-025-01246-2. PMID: 41266804; PMCID: PMC12749696.
3. Gumpert N, Sagie S, Arnedo-Pac C, Babu T, Weller C, Gonzalez-Perez A, Wang Y, Michel Todó L, Levy R, Chen X, Greenberg P, Dayan-Rubinov M, Yakubovich E, Wasserman-Bartov T, Zerbib M, Gong J, Rebernick RJ, Oliveira Tercero A, Agundez Muriel L, Benedek G, Kedmi M, Oren R, Ben-Dor S, Levin Y, Troyanskaya OG, Munzur AD, Wyatt AW, Cieslik MP, Quigley DA, Van Allen EM, Anandasabapathy N, Mateo J, Yang X, Martínez-Jiménez F, Lopez-Bigas N, Samuels Y. Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. Cancer Discov. 2026 Feb 6;16(2):250-269. doi: 10.1158/2159-8290.CD-24-1213. PMID: 41056506; PMCID: PMC12749549.
4. Bacca L, Brandariz J, Zacchi F, Zivi A, Mateo J, Labbé DP. Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications. Gene. 2025 Nov 20;972:149774. doi: 10.1016/j.gene.2025.149774. Epub 2025 Sep 22. PMID: 40992550.
5. Sanchis P, Sabater A, Lechuga J, Rada J, Seniuk R, Pascual G, Gatti M, Bizzotto J, Shepherd PDA, Yang J, Cotignola J, Vazquez E, Mateo J, Valacco P, Labanca E, Logothetis C, Gueron G, Anselmino N. PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression. Oncogene. 2025 Oct;44(38):3568-3579. doi: 10.1038/s41388-025-03511-z. Epub 2025 Aug 2. PMID: 40753365; PMCID: PMC12436191.
6. Zurita AJ, Tidwell RS, Chapin BF, Harris DR, Zhang M, Pisters LL, Aparicio A, Araujo JC, Arce-Gallego S, Zhu K, Lozano ML, Pagliaro L, Mateo J, Logothetis C, Troncoso P, Davis JW. Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. Eur Urol Oncol. 2025 Aug;8(4):1010-1019. doi: 10.1016/j.euo.2025.04.015. Epub 2025 Jul 12. PMID: 40651932.
7. Brandariz J, de Llobet L, Esquefa V, Aguilar D, Salca A, Arce-Gallego S, Cresta Morgado P, Sole A, Agundez L, Mir G, Castro N, Casals T, Oliveira A, Casanova-Salas I, Malumbres M, Carles J, Morellá-Aucejo Á, Bernardos A, Martínez-Máñez R, Mateo J, Herranz N. Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer. Mol Cancer Ther. 2025 Dec 2;24(12):1959-1976. doi: 10.1158/1535-7163.MCT-24-0903. PMID: 40601842.
8. Martin-Martin N, Garcia-Longarte S, Corres-Mendizabal J, Lazcano U, Astobiza I, Bozal-Basterra L, Herranz N, van Splunder H, Carlevaris O, Pujana-Vaquerizo M, Blasco MT, Aransay AM, Rosino A, Tudela J, Jimenez D, Martinez A, Salca A, Santos-Martín A, Rey S, Ugalde-Olano A, Gonzalo D, Graupera M, Gomis RR, Mateo J, Unda M, Gonzalez-Billalabeitia E, Loizaga-Iriarte A, Mendizabal I, Carracedo A. Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination. Genome Biol. 2025 Jun 3;26(1):154. doi: 10.1186/s13059-025-03623-5. PMID: 40462200; PMCID: PMC12135548.
9. Balaguer-Montero M, Marcos Morales A, Ligero M, Zatse C, Leiva D, Atlagich LM, Staikoglou N, Viaplana C, Monreal C, Mateo J, Hernando J, García-Álvarez A, Salvà F, Capdevila J, Elez E, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer. Cell Rep Med. 2025 Apr 15;6(4):102032. doi: 10.1016/j.xcrm.2025.102032. Epub 2025 Mar 20. PMID: 40118052; PMCID: PMC12047525.
10. Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937. doi: 10.1016/j.xcrm.2025.101937. Epub 2025 Feb 5. PMID: 39914385; PMCID: PMC11866514.
11. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Eur Urol. 2025 Jun;87(6):626-640. doi: 10.1016/j.eururo.2024.12.007. Epub 2025 Jan 23. PMID: 39848867.
12. Zacchi F, Abida W, Antonarakis ES, Bryce AH, Castro E, Cheng HH, Shandhu S, Mateo J. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. Eur Urol Oncol. 2025 Jun;8(3):818-828. doi: 10.1016/j.euo.2024.11.011. Epub 2024 Dec 5. PMID: 39638687; PMCID: PMC12797174.
13. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11. PMID: 39394013.
14. Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2025 Jan;87(1):29-46. doi: 10.1016/j.eururo.2024.09.008. Epub 2024 Sep 20. PMID: 39306478.
15. Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):447-460. doi: 10.1016/S0140-6736(25)00684-1. Epub 2025 Jul 16. PMID: 40683290.
16. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Douglas Laird A, Kennedy D, Agarwal N. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025 Aug 2;406(10502):461-474. doi: 10.1016/S0140-6736(25)00683-X. Epub 2025 Jul 16. PMID: 40683287.
18. Fracassi G, Lorenzin F, Orlando F, Gioia U, D’Amato G, Casaramona AS, Cantore T, Prandi D, Santer FR, Klocker H, d’Adda di Fagagna F, Mateo J, Demichelis F. CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. J Clin Invest. 2024 Dec 24;135(4):e179393. doi: 10.1172/JCI179393.
19. Zacchi F, Abida W, Antonarakis ES, Bryce AH, Castro E, Cheng HH, Shandhu S, Mateo J. Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. Eur Urol Oncol. 2024 Dec 4:S2588-9311(24)00273-6. doi: 10.1016/j.euo.2024.11.011. Epub ahead of print.
20. Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, Bogdan D, Gallagher L, Cieslik JP, Greening S, Lambros M, Neves R, Magraner-Pardo L, Fowler G, Ebbs B, Miranda S, Flohr P, Bianchini D, Rescigno P, Porta N, Hall E, Gurel B, Tunariu N, Sharp A, Pettit S, Stoecklein NH, Sandhu S, Quigley D, Lord CJ, Mateo J, Carreira S, de Bono J. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024 Dec 9;42(12):2113-2123.e4. doi: 10.1016/j.ccell.2024.10.015.
21. Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, Bogdan D, Gallagher L, Cieslik JP, Greening S, Lambros M, Neves R, Magraner-Pardo L, Fowler G, Ebbs B, Miranda S, Flohr P, Bianchini D, Rescigno P, Porta N, Hall E, Gurel B, Tunariu N, Sharp A, Pettit S, Stoecklein NH, Sandhu S, Quigley D, Lord CJ, Mateo J, Carreira S, de Bono J. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024 Dec 9;42(12):2113-2123.e4. doi: 10.1016/j.ccell.2024.10.015.
22. Protasoni M, López-Polo V, Stephan-Otto Attolini C, Brandariz J, Herranz N, Mateo J, Ruiz S, Fernandez-Capetillo O, Kovatcheva M, Serrano M. Cyclophilin D plays a critical role in the survival of senescent cells. EMBO J. 2024 Dec;43(23):5972-6000. doi: 10.1038/s44318-024-00259-2.
23. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11.
24. Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, Mateo J, Rathkopf D, Saad F, Tombal B. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2025 Jan;87(1):29-46. doi: 10.1016/j.eururo.2024.09.008. Epub 2024 Sep 20.
25. Mateo J, Zurita AJ. ¹⁷⁷Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot. Lancet. 2024 Sep 28;404(10459):1174-1176. doi: 10.1016/S0140-6736(24)01919-6.
26. Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A. Metastatic hormone-naïve prostate cancer: a distinct biological entity. Trends Cancer. 2024 Sep;10(9):825-841. doi: 10.1016/j.trecan.2024.06.005.
27. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7. doi: 10.1016/j.ccell.2024.06.003.
28. Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, Seed G, Carreira S, Bertan C, Fenor de La Maza MLD, Chandran K, Neeb A, Welti J, Gallagher L, Bogdan D, Crespo M, Riisnaes R, Ferreira A, Miranda S, Lu J, Shen MM, Hall E, Porta N, Westaby D, Guo C, Grochot R, Lord CJ, Mateo J, Sharp A, de Bono J. RNASEH2B loss and PARP inhibition in advanced prostate cancer. J Clin Invest. 2024 Jun 4;134(21):e178278. doi: 10.1172/JCI178278.
29. Zacchi F, Carles J, Gonzalez M, Maldonado X, Perez-Lopez R, Semidey ME, Mateo J. Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. Front Oncol. 2024 Mar 8;14:1331643. doi: 10.3389/fonc.2024.1331643.
30. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274. doi: 10.1016/j.eururo.2024.02.016.
31. Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, Mucci LA; IRONMAN Registry. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2024 Mar 1;33(3):419-425. doi: 10.1158/1055-9965.EPI-23-1207.
32. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339.
33. Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Front Med (Lausanne). 2024 Oct 24;11:1460212. doi: 10.3389/fmed.2024.1460212.
34. Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078.
35. Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domènech M, Figols M, Carles J, Suárez C, Herrero Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol Oncol. 2024 Aug;7(4):954-964. doi: 10.1016/j.euo.2023.12.012.
36. Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019.
37. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Erratum in: Nat Med. 2024 May;30(5):1505. doi: 10.1038/s41591-024-02835-9.
38. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339. Epub ahead of print. PMID: 37963304.
39. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.
40. Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res. 2023 Jan 4;29(1):81-91. doi: 10.1158/1078-0432.CCR-22-0931. PMID: 36043882; PMCID: PMC9811161.
41. Mateo J, Beltran H. Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. Eur Urol Focus. 2023 Jan;9(1):110-113. doi: 10.1016/j.euf.2022.08.004. Epub 2022 Aug 20. PMID: 35999168.
42. Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, Penault-Llorca F, Stenzinger A, Wyatt AW, Bjartell A. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. Eur Urol Oncol. 2023 Sep 13:S2588-9311(23)00166-9. doi: 10.1016/j.euo.2023.08.004. Epub ahead of print. PMID: 37714762.
43. Turpin A, Delliaux C, Parent P, Chevalier H, Escudero-Iriarte C, Bonardi F, Vanpouille N, Flourens A, Querol J, Carnot A, Leroy X, Herranz N, Lanel T, Villers A, Olivier J, Touzet H, de Launoit Y, Tian TV, Duterque-Coquillaud M. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor. Br J Cancer. 2023 Dec;129(12):1903-1914. doi: 10.1038/s41416-023-02449-x. Epub 2023 Oct 24. PMID: 37875732; PMCID: PMC10703930.
44. Grochot R, Carreira S, Miranda S, Figueiredo I, Bertan C, Rekowski J, Yuan W, Ferreira A, Riisnaes R, Neeb A, Gurel B, de Los Dolores Fenor de la Maza M, Guo C, Carmichael J, Westaby D, Mateo J, Sharp A, McVeigh TP, De Bono J. Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer. Eur Urol Open Sci. 2023 May 2;52:72-78. doi: 10.1016/j.euros.2023.04.003. PMID: 37284046; PMCID: PMC10240520.
45. Beije N, Abida W, Antonarakis ES, Castro E, de Wit R, Fizazi K, Gillessen S, Hussain M, Mateo J, Morris MJ, Olmos D, Sartor O, Sharp A, Sweeney CJ, de Bono JS. PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. Eur Urol. 2023 Sep;84(3):253-256. doi: 10.1016/j.eururo.2023.03.038. Epub 2023 Apr 20. PMID: 37087376.
46. Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon IM, Cendón-Florez Y, Gutierrez-Pecharroman A, Salles DC, Romero-Laorden N, Lorente D, González-Peramato P, Calatrava A, Alonso C, Anido U, Arévalo-Lobera S, Balmaña J, Chirivella I, Juan-Fita MJ, Llort G, Y Cajal TR, Almagro E, Alameda D, López-Casas PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio-Briones J, Sandhu S, Olmos D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. Eur J Cancer. 2023 May;185:105-118. doi: 10.1016/j.ejca.2023.02.022. Epub 2023 Mar 5. PMID: 36972661.
47. Casolino R, Johns AL, Courtot M, Lawlor RT, De Lorenzo F, Horgan D, Mateo J, Normanno N, Rubin M, Stein L, Subbiah V, Westphalen BC, Lawler M, Park K, Perdomo S, Yoshino T, Wu J, Biankin AV; Lancet Oncology Commission on Cancer Omics and Precision Oncology. Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission. Lancet Oncol. 2023 Feb;24(2):123-125. doi: 10.1016/S1470-2045(23)00007-4. PMID: 36725142.
48. Casanova-Salas I, Aguilar D, Cordoba-Terreros S, Agundez L, Brandariz J, Herranz N, Mas A, Gonzalez M, Morales-Barrera R, Sierra A, Soriano-Navarro M, Cresta P, Mir G, Simonetti S, Rodrigues G, Arce-Gallego S, Delgado-Serrano L, Agustí I, Castellano-Sanz E, Mast R, de Albert M, Celma A, Santamaria A, Gonzalez L, Castro N, Suanes MDM, Hernández-Losa J, Nonell L, Peinado H, Carles J, Mateo J. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. Cancer Cell. 2024 Jul 8;42(7):1301-1312.e7. doi: 10.1016/j.ccell.2024.06.003. PMID: 38981440.
49. Garcia-Ruiz A, Macarro C, Zacchi F, Morales-Barrera R, Grussu F, Casanova-Salas I, Sanguedolce F, Gonzalez M, Cresta-Morgado P, de Albert M, Garcia-Bennett J, Marmolejo D, Planas J, Roche S, Mast R, Zatse C, Piulats JM, Herrera-Imbroda B, Regis L, Agundez L, Olmos D, Calvo N, Escobar M, Carles J, Mateo J, Perez-Lopez R. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. 2024 Sep;86(3):272-274. doi: 10.1016/j.eururo.2024.02.016. Epub 2024 Mar 14. PMID: 38490857.
50. Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, Korbenfeld E, Kang J, Marshall H, Lai Z, Barnicle A, Poehlein C, Lukashchuk N, Hussain M. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14. PMID: 37963304.
51. Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. Erratum in: Nat Med. 2024 May;30(5):1505. doi: 10.1038/s41591-024-02835-9. PMID: 38049622; PMCID: PMC10803259.

Proyectos

A deep learning framework to predict BRCA mutations from digital pathology slides. PI: Joaquin Mateo and Raquel Perez-Lopez. Grantor: AstraZeneca and ISC-III Duration: 2025-2026
Computational modelling of tumour evolution and treatment resistance in prostate cancer. PI: Richard Norris. Grantor: Fundacion AECC Duration: 2025-2028
ctDNA profiling in metastatic prostate cancer. Grantor: Guardant Health. PI: Joaquin Mateo. Duration: 2024-2025.
Targeting Resistance: Mechanisms and Modulators of PARP Inhibitor Response in Prostate Cancer. PI: Nicolas Anselmino. Grantor: Fundación AECC. Duration: 2024-2027.
Dissecting mechanisms of resistance and the interaction between PARPi use and AR in men with prostate cancer. PI: Joaquin Mateo. Grantor: AstraZeneca. Duration: 2024-2026.
A novel liquid biopsy assay using circulating tumor extracellular vesicles to monitor prostate cancer tumor evolution and emergence of drug resistance. PI: Irene Casanova.Funded by:Prostate Cancer Foundation (PCF).Duration: 2024-2027
Development of NT1, a potent and selective best-in-class drug targeting the Androgen Receptor disordered domain for the treatment of Castration Resistant Prostate Cancer. PI: Joaquin Mateo. Grantor: Programa RETOS Colaboracion Publico-Privada, Spanish Ministry of Science. Duration: 2024-2026.
Multimodal Biomarkers for Precise Management of Metastatic Prostate Cancer. Co-PIs: Joaquin Mateo and Raquel Perez Lopez.
Grantor: Programa RETOS Colaboracion Publico-Privada, Spanish Ministry of Science. Duration: 2023-2025.
Impact of hormonal therapy-induced senescence in the immune-tumor interaction in prostate cancer. PI: Nicolas Herranz. Grantor: Spanish Ministry of Health, FIS Program. Duration: 2024-2026.
Studying intra-tumor heterogeneity in the evolution of metastatic hormone-naïve prostate cancer to castration-resistance after intensified hormonal therapy. PI: Joaquin Mateo. Grantor: Department of Defense CDMRP (United States) 2022 Call. Duration: 2023-2026.
Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays. PI: Joaquin Mateo. Grantor: US Department of Defense Congressionally-Directed Medical Research Program. Duration: 2018-2023.
Leveraging the AR-DDR interaction in de-novo metastatic prostate cancer towards precision combination therapies with PARP inhibitors. PI: Joaquin Mateo. Grantor: AECC (Fundación Asociación Española contra el Cáncer). Duration: 2020-2023.
Integrated analysis of blood circulating tumor signatures to monitor genomic evolution and therapy responses in advanced Prostate Cancer. PI: Irene Casanova-Salas Grantor: ”la Caixa” Foundation. Duration: 2021-2024.
Exploiting senescence in a two-step approach to treat advanced Prostate Cancer. PI: Nicolas Herranz. Grantor: Instituto de Salud Carlos III (ISCIII). Duration: 2021-2023.
Tumoral senescence induced by anti-cancer therapies constitutes a novel prognostic biomarker and a therapeutic target. Co-PIs: Manuel Serrano, Maria Abad, Raquel Perez and Joaquin Mateo. Grantor: AECC (Fundación Asociación Española contra el Cáncer). Duration: 2022-2026.
Prostate Cancer Genomic Evolution and Signatures of DNA Damage Repair Deficiencies. PI: Joaquin Mateo. Grantor: CRIS Cancer Foundation. Duration: 2021-2025.